BDTX-1535

Servier has secured global rights to develop and commercialize BDTX-4933, a Phase 1 targeted therapy designed to address both RAS mutations and RAF alterations in solid tumors, particularly non-small cell lung cancer.

The Ivy Brain Tumor Center is focusing on early-phase trials using pharmacokinetic and pharmacodynamic strategies to identify effective brain cancer drugs.

The Ivy Brain Tumor Center is conducting a phase 0/1 trial of BDTX-1535, a fourth-generation EGFR inhibitor, in patients with recurrent high-grade glioma.

New therapeutic approaches, including small molecules, cell therapies, and vaccines, are revitalizing glioblastoma research after 20 years of limited progress.

BDTX-1535, a fourth-generation EGFR TKI, demonstrates encouraging clinical activity in relapsed/refractory EGFR-mutant non-small cell lung cancer (NSCLC).